Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Moving in the right direction: elucidating the mechanisms of interaction between flecainide and the cardiac ryanodine receptor.

British journal of pharmacology - 1 Jun 2022

Bannister Mark L, MacLeod Kenneth T, George Christopher H

Abstract excerpt

Flecainide is used to treat catecholaminergic polymorphic ventricular tachycardia (CPVT), an arrhythmia caused by disrupted cellular Ca2+ handling following β-adrenergic stimulation. The clinical efficacy of flecainide in this context involves complex effects on multiple ion channels that may be influenced by the disease state. A compelling narrative has been constructed around flecainide's nonselective block of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Arrhythmia Agents
Share to Calcium

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Flecainide

Share to Myocytes, Cardiac

Share to Polymorphic Catecholaminergic Ventricular Tachycardia

Share to Ryanodine Receptor Calcium Release Channel

Share to Sarcoplasmic Reticulum

Share to Tachycardia, Ventricular

Source

Identifiers

PMID: 34698387
DOI: 10.1111/bph.15718

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Moving in the right direction: elucidating the mechanisms of interaction between flecainide and the cardiac ryanodine receptor.PMID 34698387Read ↗

Insights on the mechanism of flecainide in catecholaminergic polymorphic ventricular tachycardia.Semantic proximity Read ↗

Therapeutic Approaches of Ryanodine Receptor-Associated Heart Diseases.Semantic proximity Read ↗

Ca2+ signalling in cardiac muscle: the importance of balances.Semantic proximity Read ↗

[Update on the effects of ryanodine receptor 2 phosphorylation on the pathogenesis of catecholaminergic polymorphic ventricular tachycardia].Semantic proximity Read ↗

Flecainide exerts paradoxical effects on sodium currents and atrial arrhythmia in murine RyR2-P2328S hearts.Semantic proximity Read ↗

Ryanodine receptor-targeted anti-arrhythmic therapy.Semantic proximity Read ↗

Treatment of catecholaminergic polymorphic ventricular tachycardia in mice using novel RyR2-modifying drugs.Semantic proximity Read ↗

Ryanodine receptor as a new therapeutic target of heart failure and lethal arrhythmia.Semantic proximity Read ↗

Successful treatment of catecholaminergic polymorphic ventricular tachycardia with flecainide: a case report and review of the current literature.Semantic proximity Read ↗

The sarcoplasmic reticulum and arrhythmogenic calcium release.Semantic proximity Read ↗

The cardiac muscle cellSemantic proximity Read ↗

Targeting intracellular calcium cycling in catecholaminergic polymorphic ventricular tachycardia: a theoretical investigation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.